TABLE 4.
Infective factors and the CSD risk
| Parameters | Category | Counts | CSD prevalence (95% CI) | aOR (95% CI) | p |
|---|---|---|---|---|---|
| Antibiotics prophylaxis group | Experimental | 104 | 32.7 (23.5–41.9) | Reference | 0.023 |
| Placebo | 108 | 46.3 (36.7–55.9) | 2.1 (1.1–3.8) | ||
| ROM duration (h) | <24 | 165 | 34.6 (27.2–41.9) | Reference | 0.001 |
| ≥24 | 40 | 62.5 (46.8–78.2) | 1.5 (1.2–1.9) | ||
| Cervix dilatation (cm) | <6 | 174 | 37.4 (30.1–44.6) | Reference | 0.161 |
| ≥6 | 38 | 50.0 (33.3–66.6) | NA | ||
| hsCRP pre‐CS (mg/L) | <10 | 125 | 35.2 (26.7–43.7) | Reference | 0.273 |
| ≥10 | 82 | 45.1 (34.1–56.1) | NA | ||
| hsCRP post‐CS (mg/L) | < 50 | 127 | 35.4 (27.0–43.9) | Reference | 0.304 |
| ≥50 | 79 | 45.6 (34.3–56.8) | NA | ||
| Procalcitonin pre‐CS (μg/L) | < 0.05 | 92 | 34.8 (24.9–44.7) | Reference | 0.121 |
| ≥0.05 | 113 | 44.3 (35.0–53.6) | NA | ||
| Procalcitonin post‐CS (μg/L) | <0.05 | 38 | 29.0 (13.8–44.1) | Reference | 0.228 |
| ≥0.05 | 162 | 42.0 (34.3–49.7) | NA | ||
| Cervix secretion culture pre‐CS | Negative | 113 | 35.4 (26.5–44.4) | Reference | 0.465 |
| Positive | 98 | 44.9 (34.9–54.9) | NA | ||
| Uterine cavity culture in‐CS | Negative | 183 | 37.2 (30.1–44.2) | reference | 0.321 |
| Positive | 29 | 55.2 (35.9–74.4) | NA |
Note: N/A denotes not applicable. By univariate analysis of the factor associated with antibiotics prophylaxis, factors with p <0.20 were included in the logistic regression model. The adjusted odds ratios (aOR) were adjusted for cervix dilatation, pre‐/post‐CS hsCRP/ptocalcitonin, cervix secretion culture pre‐CS and uterine cavity culture in‐CS.
Abbreviations: aOR, adjusted odds ratio; CS, cesarean section; hsCRP, hypersensitive C‐reactive protein; NEU, neutrophils; ROM, rupture of membrane; WBC, white blood cell.